Brokerages expect that Proteostasis Therapeutics, Inc. (NASDAQ:PTI) will report earnings of ($0.63) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.55). Proteostasis Therapeutics reported earnings per share of ($0.54) during the same quarter last year, which would suggest a negative year over year growth rate of 16.7%. The firm is scheduled to announce its next earnings results on Thursday, November 9th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.81) to ($2.26). For the next year, analysts expect that the business will post earnings of ($2.30) per share, with EPS estimates ranging from ($2.55) to ($2.04). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Proteostasis Therapeutics.
A number of research firms recently weighed in on PTI. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a report on Friday, June 30th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $9.00 price target (down from $17.00) on shares of Proteostasis Therapeutics in a report on Wednesday, August 16th.
COPYRIGHT VIOLATION NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/09/0-63-earnings-per-share-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.
A number of hedge funds have recently made changes to their positions in PTI. Teachers Advisors LLC grew its holdings in Proteostasis Therapeutics by 21.4% during the 4th quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock worth $155,000 after acquiring an additional 2,223 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Proteostasis Therapeutics during the 1st quarter worth $100,000. Bank of New York Mellon Corp grew its holdings in Proteostasis Therapeutics by 17.3% during the 1st quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after acquiring an additional 5,153 shares in the last quarter. TD Asset Management Inc. acquired a new position in Proteostasis Therapeutics during the 1st quarter worth $199,000. Finally, Trexquant Investment LP grew its holdings in Proteostasis Therapeutics by 1.0% during the 1st quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock worth $155,000 after acquiring an additional 190 shares in the last quarter. 73.71% of the stock is owned by institutional investors.
Shares of Proteostasis Therapeutics (PTI) traded down 4.07% during trading on Monday, hitting $2.12. 36,405 shares of the company were exchanged. Proteostasis Therapeutics has a 12 month low of $1.71 and a 12 month high of $16.67. The stock’s market cap is $53.21 million. The company’s 50-day moving average price is $2.03 and its 200 day moving average price is $4.27.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.